# Agco Corp: financial statements, quarterly AGCO · NYSE · CIK 880266 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/agco.md) · [Financials](/companies/agco/financials.md) · [Filings](/companies/agco/filings.md) · [Insiders](/companies/agco/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agco/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3,801 d](/filings/0000880266-26-000010.md) | [2,929](/filings/0000880266-25-000026.md) | [3,247](/filings/0000880266-25-000044.md) | [2,599](/filings/0000880266-25-000061.md) | [2,887 d](/filings/0000880266-26-000010.md) | [2,051](/filings/0000880266-26-000057.md) | [2,635](/filings/0000880266-26-000068.md) | [2,476](/filings/0000880266-26-000077.md) | [2,920 d](/filings/0000880266-26-000010.md) | [2,343](/filings/0000880266-26-000057.md) | [2,610](/filings/0000880266-26-000068.md) | [2,263](/filings/0000880266-26-000077.md) | | Cost of revenue | $m | [2,818 d](/filings/0000880266-26-000010.md) | [2,159](/filings/0000880266-25-000026.md) | [2,409](/filings/0000880266-25-000044.md) | [1,996](/filings/0000880266-25-000061.md) | [2,199 d](/filings/0000880266-26-000010.md) | [1,530](/filings/0000880266-26-000057.md) | [1,976](/filings/0000880266-26-000068.md) | [1,830](/filings/0000880266-26-000077.md) | [2,179 d](/filings/0000880266-26-000010.md) | [1,762](/filings/0000880266-26-000057.md) | [1,964](/filings/0000880266-26-000068.md) | [1,697](/filings/0000880266-26-000077.md) | | Gross profit | $m | [983 d](/filings/0000880266-26-000010.md) | [770](/filings/0000880266-25-000026.md) | [838](/filings/0000880266-25-000044.md) | [603](/filings/0000880266-25-000061.md) | [689 d](/filings/0000880266-26-000010.md) | [521](/filings/0000880266-26-000057.md) | [659](/filings/0000880266-26-000068.md) | [647](/filings/0000880266-26-000077.md) | [741 d](/filings/0000880266-26-000010.md) | [581](/filings/0000880266-26-000057.md) | [646](/filings/0000880266-26-000068.md) | [565](/filings/0000880266-26-000077.md) | | Research and development | $m | [22.9 d](/filings/0000880266-26-000010.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Selling, general and administrative | $m | [417 d](/filings/0000880266-26-000010.md) | [350](/filings/0000880266-25-000026.md) | [380](/filings/0000880266-25-000044.md) | [344](/filings/0000880266-25-000061.md) | [323 d](/filings/0000880266-26-000010.md) | [326](/filings/0000880266-26-000057.md) | [326](/filings/0000880266-26-000068.md) | [341](/filings/0000880266-26-000077.md) | [316 d](/filings/0000880266-26-000010.md) | [339](/filings/0000880266-26-000057.md) | [336](/filings/0000880266-26-000068.md) | [304](/filings/0000880266-26-000077.md) | | Operating income | $m | [393 d](/filings/0000880266-26-000010.md) | [274](/filings/0000880266-25-000026.md) | [(242)](/filings/0000880266-25-000044.md) | [115](/filings/0000880266-25-000061.md) | [(269) d](/filings/0000880266-26-000010.md) | [49.4](/filings/0000880266-26-000057.md) | [164](/filings/0000880266-26-000068.md) | [152](/filings/0000880266-26-000077.md) | [231 d](/filings/0000880266-26-000010.md) | [80.7](/filings/0000880266-26-000057.md) | [141](/filings/0000880266-26-000068.md) | [116](/filings/0000880266-26-000077.md) | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $m | [(76.1) d](/filings/0000880266-26-000010.md) | [69.1](/filings/0000880266-25-000026.md) | [41.6](/filings/0000880266-25-000044.md) | [11.9](/filings/0000880266-25-000061.md) | [(24.2) d](/filings/0000880266-26-000010.md) | [2.0](/filings/0000880266-26-000057.md) | [(206)](/filings/0000880266-26-000068.md) | [48.8](/filings/0000880266-26-000077.md) | [77.3 d](/filings/0000880266-26-000010.md) | [4.6](/filings/0000880266-26-000057.md) | [40.4](/filings/0000880266-26-000068.md) | [25.2](/filings/0000880266-26-000077.md) | | Net income | $m | [339 d](/filings/0000880266-26-000010.md) | [168](/filings/0000880266-25-000026.md) | [(367)](/filings/0000880266-25-000044.md) | [30.0](/filings/0000880266-25-000061.md) | [(256) d](/filings/0000880266-26-000010.md) | [10.5](/filings/0000880266-26-000057.md) | [315](/filings/0000880266-26-000068.md) | [306](/filings/0000880266-26-000077.md) | [95.5 d](/filings/0000880266-26-000010.md) | [55.0](/filings/0000880266-26-000057.md) | [77.2](/filings/0000880266-26-000068.md) | [51.7](/filings/0000880266-26-000077.md) | | Diluted EPS | $ per share | not reported | [2.25](/filings/0000880266-25-000026.md) | [(4.92)](/filings/0000880266-25-000044.md) | [0.40](/filings/0000880266-25-000061.md) | not reported | [0.14](/filings/0000880266-26-000057.md) | [4.22](/filings/0000880266-26-000068.md) | [4.09](/filings/0000880266-26-000077.md) | not reported | [0.76](/filings/0000880266-26-000057.md) | [1.08](/filings/0000880266-26-000068.md) | [0.75](/filings/0000880266-26-000077.md) | | Basic EPS | $ per share | not reported | [2.25](/filings/0000880266-25-000026.md) | [(4.92)](/filings/0000880266-25-000044.md) | [0.40](/filings/0000880266-25-000061.md) | not reported | [0.14](/filings/0000880266-26-000057.md) | [4.22](/filings/0000880266-26-000068.md) | [4.10](/filings/0000880266-26-000077.md) | not reported | [0.76](/filings/0000880266-26-000057.md) | [1.08](/filings/0000880266-26-000068.md) | [0.75](/filings/0000880266-26-000077.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.6](/filings/0000880266-25-000011.md) | [2.5](/filings/0001628280-24-020216.md) | [0.7](/filings/0000880266-24-000052.md) | [0.6](/filings/0000880266-24-000059.md) | [0.6](/filings/0000880266-26-000010.md) | [0.6](/filings/0000880266-25-000026.md) | [0.8](/filings/0000880266-25-000044.md) | [0.9](/filings/0000880266-25-000061.md) | [0.9](/filings/0000880266-26-000077.md) | [0.5](/filings/0000880266-26-000057.md) | [0.6](/filings/0000880266-26-000068.md) | [0.4](/filings/0000880266-26-000077.md) | | Current assets | $bn | [6.3](/filings/0000880266-25-000011.md) | [8.4](/filings/0001628280-24-020216.md) | [6.6](/filings/0000880266-24-000052.md) | [6.5](/filings/0000880266-24-000059.md) | [5.1](/filings/0000880266-26-000010.md) | [5.3](/filings/0000880266-25-000026.md) | [5.6](/filings/0000880266-25-000044.md) | [5.7](/filings/0000880266-25-000061.md) | [5.2](/filings/0000880266-26-000077.md) | [5.3](/filings/0000880266-26-000057.md) | [5.3](/filings/0000880266-26-000068.md) | [5.2](/filings/0000880266-26-000077.md) | | Total assets | $bn | [11.4](/filings/0000880266-26-000010.md) | [13.5](/filings/0001628280-24-020216.md) | [13.6](/filings/0000880266-24-000052.md) | [13.5](/filings/0000880266-24-000059.md) | [11.2](/filings/0000880266-26-000010.md) | [11.5](/filings/0000880266-25-000026.md) | [12.3](/filings/0000880266-25-000044.md) | [12.5](/filings/0000880266-25-000061.md) | [11.9](/filings/0000880266-26-000077.md) | [12.0](/filings/0000880266-26-000057.md) | [11.9](/filings/0000880266-26-000068.md) | [11.7](/filings/0000880266-26-000077.md) | | Current liabilities | $bn | [4.3](/filings/0000880266-25-000011.md) | [4.2](/filings/0001628280-24-020216.md) | [4.4](/filings/0000880266-24-000052.md) | [4.3](/filings/0000880266-24-000059.md) | [3.8](/filings/0000880266-26-000010.md) | [3.5](/filings/0000880266-25-000026.md) | [3.8](/filings/0000880266-25-000044.md) | [3.6](/filings/0000880266-25-000061.md) | [3.7](/filings/0000880266-26-000077.md) | [4.1](/filings/0000880266-26-000057.md) | [4.0](/filings/0000880266-26-000068.md) | [3.9](/filings/0000880266-26-000077.md) | | Total liabilities | $bn | [6.8](/filings/0000880266-25-000011.md) | [8.7](/filings/0001628280-24-020216.md) | [9.1](/filings/0000880266-24-000052.md) | [9.0](/filings/0000880266-24-000059.md) | [7.1](/filings/0000880266-26-000010.md) | [7.4](/filings/0000880266-25-000026.md) | [7.8](/filings/0000880266-25-000044.md) | [7.7](/filings/0000880266-25-000061.md) | [7.4](/filings/0000880266-26-000077.md) | [7.4](/filings/0000880266-26-000057.md) | [7.5](/filings/0000880266-26-000068.md) | [7.4](/filings/0000880266-26-000077.md) | | Long-term debt | $bn | [1.4](/filings/0000880266-25-000011.md) | [3.4](/filings/0001628280-24-020216.md) | [3.6](/filings/0000880266-24-000052.md) | [3.6](/filings/0000880266-24-000059.md) | [2.2](/filings/0000880266-26-000010.md) | [2.8](/filings/0000880266-25-000026.md) | [2.8](/filings/0000880266-25-000044.md) | [2.7](/filings/0000880266-25-000061.md) | [2.3](/filings/0000880266-26-000077.md) | [2.0](/filings/0000880266-26-000057.md) | [2.2](/filings/0000880266-26-000068.md) | [2.1](/filings/0000880266-26-000077.md) | | Current portion of debt | $bn | [0.0](/filings/0000880266-25-000011.md) | [0.3](/filings/0001628280-24-020216.md) | [0.3](/filings/0000880266-24-000052.md) | [0.4](/filings/0000880266-24-000059.md) | [0.4](/filings/0000880266-26-000010.md) | [0.2](/filings/0000880266-25-000026.md) | [0.2](/filings/0000880266-25-000044.md) | [0.1](/filings/0000880266-25-000061.md) | [0.1](/filings/0000880266-26-000077.md) | [0.6](/filings/0000880266-26-000057.md) | [0.5](/filings/0000880266-26-000068.md) | [0.5](/filings/0000880266-26-000077.md) | | Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $bn | [4.7](/filings/0000880266-25-000011.md) | [4.8](/filings/0001628280-24-020216.md) | [4.1](/filings/0000880266-24-000052.md) | [4.1](/filings/0000880266-24-000059.md) | [3.7](/filings/0000880266-26-000010.md) | [3.8](/filings/0000880266-25-000026.md) | [4.2](/filings/0000880266-25-000044.md) | [4.5](/filings/0000880266-25-000061.md) | [4.3](/filings/0000880266-26-000077.md) | [4.3](/filings/0000880266-26-000057.md) | [4.1](/filings/0000880266-26-000068.md) | [4.1](/filings/0000880266-26-000077.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:DebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [900 d](/filings/0000880266-26-000010.md) | [(370)](/filings/0000880266-25-000026.md) | [236 d](/filings/0000880266-25-000044.md) | [26.5 d](/filings/0000880266-25-000061.md) | [798 d](/filings/0000880266-26-000010.md) | [(212)](/filings/0000880266-26-000057.md) | [366 d](/filings/0000880266-26-000068.md) | [71.0 d](/filings/0000880266-26-000077.md) | [764 d](/filings/0000880266-26-000010.md) | [(410)](/filings/0000880266-26-000057.md) | [165 d](/filings/0000880266-26-000068.md) | [26.6 d](/filings/0000880266-26-000077.md) | | Capital expenditure | $m | [160 d](/filings/0000880266-26-000010.md) | [95.0](/filings/0000880266-25-000026.md) | [98.0 d](/filings/0000880266-25-000044.md) | [86.3 d](/filings/0000880266-25-000061.md) | [114 d](/filings/0000880266-26-000010.md) | [48.2](/filings/0000880266-26-000057.md) | [42.2 d](/filings/0000880266-26-000068.md) | [68.9 d](/filings/0000880266-26-000077.md) | [88.6 d](/filings/0000880266-26-000010.md) | [44.6](/filings/0000880266-26-000057.md) | [57.2 d](/filings/0000880266-26-000068.md) | [60.4 d](/filings/0000880266-26-000077.md) | | Dividends paid | $m | [21.6 d](/filings/0000880266-26-000010.md) | [21.6](/filings/0000880266-25-000026.md) | [208 d](/filings/0000880266-25-000044.md) | [21.6 d](/filings/0000880266-25-000061.md) | [21.6 d](/filings/0000880266-26-000010.md) | [21.6](/filings/0000880266-26-000057.md) | [21.7 d](/filings/0000880266-26-000068.md) | [21.6 d](/filings/0000880266-26-000077.md) | [21.6 d](/filings/0000880266-26-000010.md) | [21.0](/filings/0000880266-26-000057.md) | [21.0 d](/filings/0000880266-26-000068.md) | [20.7 d](/filings/0000880266-26-000077.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0000880266-26-000077.md) | [250 d](/filings/0000880266-26-000010.md) | not reported | not reported | [56.7 d](/filings/0000880266-26-000077.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [75.0](/filings/0001628280-24-020216.md) | [75.0](/filings/0000880266-24-000052.md) | [75.0](/filings/0000880266-24-000059.md) | [74.7](/filings/0000880266-25-000026.md) | [74.7](/filings/0000880266-25-000044.md) | [74.7](/filings/0000880266-25-000061.md) | [74.7](/filings/0000880266-26-000057.md) | [74.6](/filings/0000880266-26-000068.md) | [74.7](/filings/0000880266-26-000077.md) | [72.7](/filings/0000880266-26-000057.md) | [71.2](/filings/0000880266-26-000068.md) | [69.5](/filings/0000880266-26-000077.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 68,950,835 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0000880266-26-000077.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 12:11 ET. No prices; not investment advice.